Filing Details

Accession Number:
0001104659-15-049012
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-06-30 18:45:33
Reporting Period:
2015-06-30
Filing Date:
2015-06-30
Accepted Time:
2015-06-30 18:45:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1454789 Catabasis Pharmaceuticals Inc CATB Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1291884 Medimmune Ventures, Inc. One Medimmune Way
Gaithersburg MD 20878
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-06-30 1,079,115 $0.00 1,079,115 No 4 C Direct
Common Stock Acquisiton 2015-06-30 330,098 $0.00 1,409,213 No 4 C Direct
Common Stock Acquisiton 2015-06-30 223,439 $12.00 1,632,652 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2015-06-30 13,866,666 $0.00 1,079,115 $0.00
Common Stock Series B Preferred Stock Disposition 2015-06-30 4,241,780 $0.00 330,098 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. The Series A and Series B Preferred Stock converted into Common Stock on a 1-for-12.85 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A and B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
  2. These shares are owned directly by MedImmune Ventures, Inc. Ron Laufer is the Senior Managing Partner of MedImmune Ventures, Inc., and as a result, Dr. Laufer may be deemed to hold voting, dispositive and investment power over the shares held by MedImmune Ventures, Inc. Dr. Laufer disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.